ADM Korea Inc.

Equities

A187660

KR7187660006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3,545 ^KRW	+0.85%		-2.61%	+82.92%

Mar. 11	Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	CI
2023	ADM Korea Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.

March 10, 2024

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion on March 11, 2024. Transaction is expected to May 20, 2024.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
HYUNDAI BIOSCIENCE CO., LTD.	19,860 KRW	-0.30%	-1.93%	575M
ADM KOREA INC.	3,545 KRW	+0.85%	-2.61%	54.48M
MOBIIS CO., LTD.	3,375 KRW	+0.45%	+4.65%	78.32M

Latest news about ADM Korea Inc.

Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	Mar. 10	CI
ADM Korea Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tranche Update on ADM Korea Inc.'s Equity Buyback Plan announced on April 22, 2022.	22-10-24	CI
Tranche Update on ADM Korea Inc.'s Equity Buyback Plan announced on April 22, 2022.	22-10-24	CI
Tranche Update on ADM Korea Inc.'s Equity Buyback Plan announced on April 22, 2022.	22-10-24	CI
ADM Korea Inc.'s Equity Buyback announced on April 22, 2022, has expired with 683,321 shares, representing 3.13% for KRW 2,737.04 million.	22-10-20	CI
ADM Korea Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	22-04-22	CI
ADM Korea Inc. authorizes a Buyback Plan.	22-04-21	CI
ADM Korea Inc. announced that it has received KRW 9.9999584 billion in funding from Hanyang Securities Co. Ltd., Mirae Asset Securities Co., Ltd.	22-04-19	CI
ADM Korea Inc. announced that it expects to receive KRW 9.9999584 billion in funding from Hanyang Securities Co. Ltd., Mirae Asset Securities Co., Ltd. and other investors	22-04-11	CI
ADM Korea Inc. announced that it has received KRW 5.9990385 billion in funding from Industrial Bank of Korea	19-04-29	CI
ADM Korea Inc. announced that it expects to receive KRW 5.9990385 billion in funding from Industrial Bank of Korea	19-04-28	CI
Mobiis Co., Ltd. completed the acquisition of 43.9% stake in ADM Korea Inc. from Mihyun Cho.	19-01-13	CI
Mobiis Co., Ltd. agreed to acquire 43.9% stake in ADM Korea Inc. from Mihyun Cho for KRW 8.8 billion.	18-12-13	CI
Seokmin Yoon, President, Chief Executive Officer and representative Director of ADM Korea Inc. cancelled the acquisition of 25.1% stake in ADM Korea Inc. from EPS International Co., Ltd.	12-03-28	CI

Chart ADM Korea Inc.

Duration

Period

More charts

Company Profile

ADM Korea Inc is a Korea-based company primarily engaged in the provision of clinical trial services. The Company is a contract research organization (CRO) that provides clinical trial related services to pharmaceutical companies and bio ventures. The Company also provides post-marketing research (rPMS) services.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADM KOREA INC.	+82.92%	54.48M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research